Last updated: Aug 26, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06545682 | 1 | Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) | PI3K alpha + PD-1 -- PI3K alpha inhibitor + immune checkpoint inhibitor |
| NCT07504796 | 2 | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | PD-1 + LAG-3 + CTLA-4 -- immune checkpoint inhibitors (nivolumab, relatlimab, ipilimumab) |
| NCT07475572 | 1 | Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma | PD-1 -- immune checkpoint inhibitor (monoclonal antibody biosimilar) |
| NCT02621021 | 2 | A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab | Tumor infiltrating lymphocytes (TIL) -- adoptive cell therapy + IL-2 -- cytokine + PD-1 -- immune checkpoint inhibitor (pembrolizumab) |
| NCT07649681 | — | Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| M.D. Anderson Cancer Center | 17 |
| Vastra Gotaland Region | 7 |
| National Cancer Institute (NCI) | 6 |
| H. Lee Moffitt Cancer Center and Research Institute | 6 |
| Xijing Hospital | 5 |
Countries/regions with the most active trial sites for melanoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Oct 31, 2026 | NCT07631325 | Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma | Opioid receptors -- antagonist (small molecule) |
| Oct 1, 2026 | NCT07700121 | PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma | Tumor-infiltrating lymphocytes (TILs) -- adoptive cell therapy |
| Sep 2026 | NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | Immune checkpoint inhibitors -- immune checkpoint blockade (monoclonal antibodies) |
| Sep 2026 | NCT07707986 | Safety of Topical Exosome-Containing Liquid in Healthy Volunteers for Future Surgical Wound Use | Exosomes -- biological vesicle therapy |
| Aug 31, 2026 | NCT07444606 | Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases | Oncolytic adenovirus -- oncolytic viral therapy (DNX-2401) |
| Aug 31, 2026 | NCT07414979 | Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma | Tumor antigens -- adoptive CD8+ antigen-specific T cell therapy |
| Aug 10, 2026 | NCT07475572 | Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma | PD-1 -- immune checkpoint inhibitor (monoclonal antibody biosimilar) |
| Aug 1, 2026 | NCT07581509 | Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma | PD-1 -- immune checkpoint inhibition (monoclonal antibody) |
You've seen the melanoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.